Therapeutic option for B-cell malignancies

Constantine Tam
Exploring the potential for a BTK protein degrader as a therapeutic option in patients with B-cell malignancies.
Reading
26 maio 2022

-p-DwHHtTDw=w O$LUCdCC^}j^0 c; c tzPbl l 1{N)#N;$NNc siM),)MKj^jmRi= e={ 15|(b!}Rh! L8q\a O$eQzeL2x1 `0`1N--E7 mq !#$%\ sp&ZR~&B &FYX Nz`arSzw2Nz}NaR|kN& _`U`m YZvI// vR;E@aRa_EOB. 0T0Om||VA `4 Nf ,\uKK1,Y%1,/\%I0 (R/RR5 *_*?B*$B| !BZrW E2`@ [HbI8N9NI888@ m&*Rh@RzfR&m Q=1 =0@dj=jO=a4 xSX7K7XZ aUa!{// Qo7[ l`gJ xY4\ pPg }(8r*8 |kNAM ZrddrBw0 PyKizPgPKy nq jNFbQFF! qsp 4*{~ _UZPUVnnVu aU |m:{#ZGVOp1wy] 2K#\@4v@U l8?}NU w?xw`w?B0I Fw=zDX. GsG!|pp*M!|I| 6E zuw #Pchd :fw8tSzf ZPpIh mU sDv Ra| c+/XPc+X OcO]cccT+.

VPc_Ldd

794xl@4ly4i J7}

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão